FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2639253133> ?p ?o ?g. }

• W2639253133 endingPage "4505" @default.
• W2639253133 startingPage "4505" @default.
• W2639253133 abstract "Abstract Introduction: Cyclophosphamide, bortezomib and Dexamethasone (CyBorD) has become the standard frontline approach for the treatment of multiple myeloma (MM) in many centers across Canada. A recent study led by the IFM group showed that the triplet combination of bortezomib, thalidomide and dexamethasone is superior as an induction regimen compared to CyBorD for patients undergoing ASCT. Based on the above-mentioned, we aimed to compare the effect of CyBorD and VTD for the treatment of transplant eligible MM patients in 2 different centers from Canada and Spain. Patients and Methods: The primary objective was to assess ORR and ³VGPR rates after induction and at day-100 post-ASCT, as well as MRD assessed by flow cytometry. Two-sided Fisher exact test was used to test for differences between categorical variables. A p value of <0.05 was considered significant and survival curves were constructed according to the Kaplan-Meier method and compared using the log rank test. Results: 101 patients have received CyBorD and 23 have received VTD. Clinical characteristics are shown in Table 1. At the time of analysis, 90 and 19 patients in the CyBorD and VTD are alive of which 25 and 9, respectively, have progressed. ORR and VGPR rates after a median of 4 cycles of induction were 94% and 56.4% for patients treated with CyBorD, and 91% and 78.2% for VTD, respectively (p=0.3 and 0.05). At day-100 post-ASCT, a ³VGPR rate of 84% and 94% was observed for the CyBorD and VTD groups, respectively (p=0.2). MRD negativity and CR rates were higher in the group receiving VTD (36.8% vs 27%, and 61% vs 38%, p=0.3 and 0.01). Furthermore, median OS and PFS did not differ among both groups (p=0.8 and 0.9, respectively) (Fig1a and Fig1b). In Conclusion: CyBorD and VTD appeared to be effective treatment options for transplant-eligible myeloma patients with similar response rates. Our study is in agreement with that reported by the IFM group, showing a higher rate of³VGPR after induction and day-100 post-ASCT in the VTD group. MRD negativity and CR rate appears also higher in the VTD group suggesting a higher degree of response by using animmunomodulatory drug and a proteasome inhibitor together. Overall Survival according to treatment regimen Overall Survival according to treatment regimen Figure 1 Progression-Free survival according to treatment regimen Figure 1. Progression-Free survival according to treatment regimen Disclosures Jimenez-Zepeda: Takeda: Honoraria; Amgen: Honoraria; Janssen: Honoraria; Celgene, Janssen, Amgen, Onyx: Honoraria. Bahlis:Janssen: Consultancy, Honoraria, Other: Travel Expenses, Research Funding, Speakers Bureau; Amgen: Consultancy, Honoraria; Onyx: Consultancy, Honoraria; Celgene: Consultancy, Honoraria, Other: Travel Expenses, Research Funding, Speakers Bureau; BMS: Honoraria. Neri:Celgene and Jannsen: Consultancy, Honoraria." @default.
• W2639253133 created "2017-06-30" @default.
• W2639253133 creator A5012254672 @default.
• W2639253133 creator A5020420490 @default.
• W2639253133 creator A5034182883 @default.
• W2639253133 creator A5034837494 @default.
• W2639253133 creator A5043652802 @default.
• W2639253133 creator A5047475074 @default.
• W2639253133 creator A5048122779 @default.
• W2639253133 creator A5064430852 @default.
• W2639253133 creator A5065238694 @default.
• W2639253133 date "2016-12-02" @default.
• W2639253133 modified "2023-10-18" @default.
• W2639253133 title "Cyclophosphamide, Bortezomib and Dexamethasone (CyBorD) Compared to Bortezomib, Thalidomide and Dexamethasone (VTD) As Induction Therapy for the Treatment of Transplant Eligible Multiple Myeloma" @default.
• W2639253133 doi "https://doi.org/10.1182/blood.v128.22.4505.4505" @default.
• W2639253133 hasPublicationYear "2016" @default.
• W2639253133 type Work @default.
• W2639253133 sameAs 2639253133 @default.
• W2639253133 citedByCount "4" @default.
• W2639253133 countsByYear W26392531332019 @default.
• W2639253133 countsByYear W26392531332020 @default.
• W2639253133 countsByYear W26392531332022 @default.
• W2639253133 crossrefType "journal-article" @default.
• W2639253133 hasAuthorship W2639253133A5012254672 @default.
• W2639253133 hasAuthorship W2639253133A5020420490 @default.
• W2639253133 hasAuthorship W2639253133A5034182883 @default.
• W2639253133 hasAuthorship W2639253133A5034837494 @default.
• W2639253133 hasAuthorship W2639253133A5043652802 @default.
• W2639253133 hasAuthorship W2639253133A5047475074 @default.
• W2639253133 hasAuthorship W2639253133A5048122779 @default.
• W2639253133 hasAuthorship W2639253133A5064430852 @default.
• W2639253133 hasAuthorship W2639253133A5065238694 @default.
• W2639253133 hasConcept C126322002 @default.
• W2639253133 hasConcept C141071460 @default.
• W2639253133 hasConcept C143998085 @default.
• W2639253133 hasConcept C2776063141 @default.
• W2639253133 hasConcept C2776364478 @default.
• W2639253133 hasConcept C2776694085 @default.
• W2639253133 hasConcept C2776755627 @default.
• W2639253133 hasConcept C2777478702 @default.
• W2639253133 hasConcept C2779050716 @default.
• W2639253133 hasConcept C2779609412 @default.
• W2639253133 hasConcept C2780401358 @default.
• W2639253133 hasConcept C2781413609 @default.
• W2639253133 hasConcept C71924100 @default.
• W2639253133 hasConcept C90924648 @default.
• W2639253133 hasConceptScore W2639253133C126322002 @default.
• W2639253133 hasConceptScore W2639253133C141071460 @default.
• W2639253133 hasConceptScore W2639253133C143998085 @default.
• W2639253133 hasConceptScore W2639253133C2776063141 @default.
• W2639253133 hasConceptScore W2639253133C2776364478 @default.
• W2639253133 hasConceptScore W2639253133C2776694085 @default.
• W2639253133 hasConceptScore W2639253133C2776755627 @default.
• W2639253133 hasConceptScore W2639253133C2777478702 @default.
• W2639253133 hasConceptScore W2639253133C2779050716 @default.
• W2639253133 hasConceptScore W2639253133C2779609412 @default.
• W2639253133 hasConceptScore W2639253133C2780401358 @default.
• W2639253133 hasConceptScore W2639253133C2781413609 @default.
• W2639253133 hasConceptScore W2639253133C71924100 @default.
• W2639253133 hasConceptScore W2639253133C90924648 @default.
• W2639253133 hasIssue "22" @default.
• W2639253133 hasLocation W26392531331 @default.
• W2639253133 hasOpenAccess W2639253133 @default.
• W2639253133 hasPrimaryLocation W26392531331 @default.
• W2639253133 hasRelatedWork W1972705137 @default.
• W2639253133 hasRelatedWork W1999964913 @default.
• W2639253133 hasRelatedWork W2009883886 @default.
• W2639253133 hasRelatedWork W2013163224 @default.
• W2639253133 hasRelatedWork W2025081120 @default.
• W2639253133 hasRelatedWork W2067463209 @default.
• W2639253133 hasRelatedWork W2089651698 @default.
• W2639253133 hasRelatedWork W2160188479 @default.
• W2639253133 hasRelatedWork W2884725265 @default.
• W2639253133 hasRelatedWork W3127479238 @default.
• W2639253133 hasVolume "128" @default.
• W2639253133 isParatext "false" @default.
• W2639253133 isRetracted "false" @default.
• W2639253133 magId "2639253133" @default.
• W2639253133 workType "article" @default.